Wells Fargo Sees 112% Upside in Design Therapeutics Ahead of 2027 Friedreich Ataxia Data
Analysts see GeneTAC protein gains translating into functional benefit in Friedreich ataxia. Cash of $207.4 million is guided to fund plans into 2029.
Analysts see GeneTAC protein gains translating into functional benefit in Friedreich ataxia. Cash of $207.4 million is guided to fund plans into 2029.
Design Therapeutics’ DT-216P2 improved Friedreich ataxia symptoms in early trial, increased frataxin levels and was well tolerated with no serious side effects.
Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).
Bank of America and Piper Sandler make bullish moves on top biotech stocks, including Regeneron, Erasca, Protara, Design Therapeutics, and Oric, highlighting growth potential, new drug updates, and pipeline opportunities.
RBC Capital upgrades Design Therapeutics to Outperform with a new $13 price target, citing promising 2026 milestones, positive data potential, and long-term revenue upside.